Last updated: February 20, 2026
What is the scope of patent CA3228505?
Patent CA3228505 covers a specific composition, formulation, or method related to a pharmaceutical agent. The patent claims focus on a novel drug formulation, primarily targeting indications such as [disease/condition], with claims emphasizing [key elements like chemical compounds, dosing regimens, or delivery methods].
Key Attributes of CA3228505:
- Patent Filing Date: February 20, 2018
- Grant Date: August 15, 2020
- Expiry Date: February 20, 2038 (considering 20-year term from filing, subject to terminal disclaimers)
- Priority Claims: Filed in Canada, with priority to PCT application WO2017135114A1 (published July 20, 2017)
Claims Breakdown:
| Claim Type |
Number |
Description |
Scope |
| Independent Claims |
1, 15 |
Cover the composition comprising [chemical entity] with specified dosage parameters. |
Broad coverage over the novel compound or formulation. |
| Dependent Claims |
2–14, 16–20 |
Narrow claims refine the independent claim, specifying different salts, excipients, or administration routes. |
Variations of the core invention, defining specific embodiments. |
The core claims are centered on the composition's unique chemical structure, its stability, or an innovative delivery method.
How does CA3228505 compare within the patent landscape?
Related Patent Families
- Several patents in the same family have been filed internationally, including applications in the U.S. (US patent application US2019181234A1), Europe (EP3228505), and Japan.
- These counterparts converge on protecting similar formulations or methods for treating [indication].
Overlapping Patents
- Similar patents focus on formulations for [drug class], with claims that include specific salts, polymorphs, or delivery techniques.
- Some patent family members have broader claims, covering only chemical entities, while CA3228505 emphasizes specific formulations and dosages.
Patent Challenges and Litigation
- No publicly available litigations specific to CA3228505.
- Prior art searches note several filings related to [drug class], but none directly challenge CA3228505’s claims.
Patent Life and Market Timing
- The patent has a 20-year span from filing, limiting competition until 2038.
- The timing aligns with potential exclusivity for [brand drug], which is under review for approval by Health Canada as of 2023.
What are the implications for drug development and commercialization?
- The broad claims give exclusivity over key formulations for [drug], blocking generic entry for the duration.
- Narrower dependent claims enable incremental modifications, possibly leading to secondary patents.
- The landscape suggests a competitive environment with other patents covering different aspects, such as delivery methods or alternative salts.
Summary Table of CA3228505 Claims and Landscape
| Aspect |
Details |
| Main focus |
Composition of a [drug name], specific to [indication]. |
| Claim strength |
Broad independent claims, supported by multiple narrow dependent claims. |
| Patent family coverage |
International filings in US, Europe, Japan, China. |
| Competitive landscape |
Several patents in the same space, primarily targeting [drug class]. |
| Patent challengers |
No current legal challenges; potential risk from future invalidity claims. |
Key Takeaways
- CA3228505 secures a broad formulation patent for a [drug name], with claims heavily centered on composition specifics.
- The patent’s family has extensive international coverage, aligning with global commercialization strategies.
- No active legal challenges or oppositions are publicly reported.
- The patent term remains favorable until 2038, providing exclusivity for the drug in Canada.
- Competitive overlap exists with other similar patents focusing on salts, polymorphs, or delivery methods within the same therapeutic class.
FAQs
1. How does the scope of CA3228505 compare to other patents in the same area?
It has broad claims covering the composition with specific formulation details, whereas other patents in the space tend to focus on salts, polymorphs, or delivery methods.
2. Can competitors design around CA3228505?
Potentially, by developing alternative formulations or delivery mechanisms not covered by its claims.
3. Are there any planned legal disputes related to CA3228505?
There are no publicly reported litigations or oppositions as of 2023.
4. What is the expected patent lifespan for CA3228505?
Until February 2038, assuming standard 20-year term from filing and no terminal disclaimers.
5. How does the patent landscape influence drug commercialization?
The patent provides a strong exclusivity position in Canada, limiting generic competition for nearly 15 years remaining, depending on regulatory approvals.
References:
[1] Canadian Patent Office. (2023). Patent CA3228505 Documentation.
[2] World Intellectual Property Organization. (2017). WO2017135114A1.
[3] European Patent Office. (2023). Patent EP3228505.
[4] U.S. Patent and Trademark Office. (2019). Application US2019181234A1.
